Erratum: Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis (European Respiratory Journal (2018) 52 (1800230) DOI: 10.1183/13993003.00230-2018);Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis

European Respiratory Journal

Volumn 52, Issue 2, 2018, Pages

  Flaherty, Kevin R ^a   Fell, Charlene D ^b   Huggins, J Terrill ^c   Nunes, Hilario ^d   Sussman, Robert ^e   Valenzuela, Claudia ^f   Petzinger, Ute ^g   Stauffer, John L ^h   Gilberg, Frank ⁱ   Bengus, Monica ⁱ   Wijsenbeek, Marlies ^j  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF CALGARY   (Canada)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d AVICENNE HOSPITAL   (France)

^e Atlantic Health   (United States)

^f Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa   (Spain)

^g ACCOVION GMBH   (Germany)

^h GENENTECH INC   (United States)

ⁱ F HOFFMANN LA ROCHE LTD   (Switzerland)

^j ERASMUS MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARBON MONOXIDE; NINTEDANIB; PIRFENIDONE; INDOLE DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDONE DERIVATIVE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; DECREASED APPETITE; DEEP VEIN THROMBOSIS; DIARRHEA; DIZZINESS; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EPIGASTRIC DISCOMFORT; FATIGUE; FEMALE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HEADACHE; HUMAN; LUNG DIFFUSION CAPACITY; MAJOR CLINICAL STUDY; MALAISE; MALE; MEDICAL ASSESSMENT; MIGRAINE; NAUSEA; PHASE 4 CLINICAL TRIAL; PHOTOSENSITIVITY; PRIORITY JOURNAL; RASH; VERY ELDERLY; VOMITING; CLINICAL TRIAL; COMBINATION DRUG THERAPY; INTERNATIONAL COOPERATION; LUNG; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; TREATMENT OUTCOME; VITAL CAPACITY;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INDOLES; INTERNATIONALITY; LUNG; MALE; MIDDLE AGED; PYRIDONES; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 85051499991     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.50230-2018     Document Type: Erratum

References (33)

1. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 183: 431-440.
2. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824.
3. American Cancer Society. Cancer Facts & Figures 2017. 2017. www.cancer.org/content/dam/cancer-org/research/ cancer-facts-and-statistics/annual-cancer-facts-and-figures/2017/cancer-facts-and-figures-2017.pdf Date last accessed: January 15, 2018.
4. Nathan SD, Shlobin OA, Weir N, et al. Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium. Chest 2011; 140: 221-229.
5. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018; 68: 7-30.
6. Food and Drug Administration. Highlights of Prescribing Information Ofev. 2017. www.accessdata.fda.gov/ drugsatfda-docs/label/2017/205832s004lbl.pdf Date last accessed: March 29, 2018.
7. Genentech. Product label: Full prescribing information - Esbriet. 2017. www.gene.com/download/pdf/esbriet- prescribing.pdf Date last accessed: January 26, 2018.
8. Raghu G, Rochwerg B, Zhang Y, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: Treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med 2015; 192: E3-e19.
9. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): Two randomised trials. Lancet 2011; 377: 1760-1769.
10. King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2083-2092.
11. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2071-2082.
12. Didiasova M, Singh R, Wilhelm J, et al. Pirfenidone exerts antifibrotic effects through inhibition of GLI transcription factors. FASEB J 2017; 31: 1916-1928.
13. European Medicines Agency. Summary of Product Characteristics - Esbriet (pirfenidone). 2017. www.ema.europa. eu/docs/en-GB/document-library/EPAR-Product-Information/human/002154/WC500103049.pdf Date last accessed: March 27, 2018.
14. European Medicines Agency. Summary of Product Characteristics - Ofev (nintedanib). 2017. www.ema.europa.eu/ docs/en-GB/document-library/EPAR-Product-Information/human/003821/WC500182474.pdf Date last accessed: March 27, 2018.
15. Lehtonen ST, Veijola A, Karvonen H, et al. Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis. Respir Res 2016; 17: 14.
16. King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet 2011; 378: 1949-1961.
17. Knuppel L, Ishikawa Y, Aichler M, et al. A novel antifibrotic mechanism of nintedanib and pirfenidone. Inhibition of collagen fibril assembly. Am J Respir Cell Mol Biol 2017; 57: 77-90.
18. Richeldi L, Cottin V, du Bois RM, et al. Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS trials. Respir Med 2016; 113: 74-79.
19. Ogura T, Taniguchi H, Azuma A, et al. Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2015; 45: 1382-1392.
20. Taniguchi H, Ogura T, Inoue Y, et al. Long-term safety of combination therapy with nintedanib and pirfenidone in Japanese patients with IPF. Eur Respir J 2016; 48: PA2089.
21. Vancheri C, Kreuter M, Richeldi L, et al. Nintedanib with add-on pirfenidone in idiopathic pulmonary fibrosis: Results of the INJOURNEY trial. Am J Respir Crit Care Med 2018; 197: 356-363.
22. Patel AS, Siegert RJ, Brignall K, et al. The development and validation of the King's Brief Interstitial Lung Disease (K-BILD) health status questionnaire. Thorax 2012; 67: 804-810.
23. US Dept of Health and Human Services, Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0. 2010. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-57.pdf Date last accessed: January 30, 2018.
24. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone for idiopathic pulmonary fibrosis: Analysis of pooled data from three multinational phase 3 trials. Eur Respir J 2016; 47: 243-253.
25. Corte T, Bonella F, Crestani B, et al. Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis. Respir Res 2015; 16: 116.
26. Lancaster LH, de Andrade J, Zibrak JD, et al. Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis. Eur Respir Rev 2017; 26: 170057.
27. Lalla D, Bengston L, Raimundo K, et al. Pirfenidone and nintedanib compliance and persistence in a real world setting [poster presentation at the American Thoracic Society Conference 2017]. Am J Respir Crit Care Med 2017; 195: A5351.
28. Costabel U, Bendstrup E, Cottin V, et al. Pirfenidone in idiopathic pulmonary fibrosis: Expert panel discussion on the management of drug-related adverse events. Adv Ther 2014; 31: 375-391.
29. Cottin V. The safety and tolerability of nintedanib in the treatment of idiopathic pulmonary fibrosis. Expert Opin Drug Saf 2017; 16: 857-865.
30. Cottin V, Koschel D, Gunther A, et al. Long-term safety of pirfenidone in a real-world setting: Final results from the prospective, observational PASSPORT registry [poster presentation at the European Respiratory Society International Congress 2017]. Eur Respir J 2017; 50: Suppl. 61, PA2806.
31. Nathan SD, Lancaster L, Albera C, et al. Dose modifications and dose intensity during treatment with pirfenidone [oral presentation at the European Respiratory Society International Congress 2016]. Eur Respir J 2016; 48: Suppl. 60, OA1764.
32. Wuyts WA, Antoniou KM, Borensztajn K, et al. Combination therapy: The future of management for idiopathic pulmonary fibrosis? Lancet Respir Med 2014; 2: 933-942.
33. Sitbon O, Gaine S. Beyond a single pathway: Combination therapy in pulmonary arterial hypertension. Eur Respir Rev 2016; 25: 408-417.